Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PGV001 in advanced non-hematologic malignancies
NCT02721043Phase 1Completed
- Sponsor
- Nina Bhardwaj
- Start
- Apr 2016
- Primary completion
- Nov 2019
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PGV-001 in solid tumor and multiple myeloma (MM), sponsored by Nina Bhardwaj. Primary endpoints: Dose-limiting toxicities and Toxicity grading using CTCAE scale at 1 year. Started Apr 2016; status: completed.
02
Drugs
PGV-001
03
Conditions
solid tumormultiple myeloma (MM)
Beyond the preview
Go deeper on NCT02721043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721043.